Comparison between functional and non-functional adrenocortical carcinoma

Alaa Sada, Malke Asaad, Katherine A. Bews, Geoffrey B. Thompson, William Francis Young, Irina Bancos, David R. Farley, Benzon M. Dy, Melanie L. Lyden, Elizabeth B Habermann, Travis J. McKenzie

Research output: Contribution to journalArticle

Abstract

Background: While roughly half of adrenocortical carcinomas are functional, whether functional status impacts outcomes remains controversial. We compared presentation and survival for functional and nonfunctional neoplasms. Methods: Adult patients presented with adrenocortical carcinomas at the Mayo Clinic were included. Tumor characteristics and outcomes were analyzed. Results: The 266 identified patients presented with stage I (6%), II (33%), III (26%), and IV disease (32%); stage was unknown in 3%. Fifty-three percent of tumors were functional; patients with functional adrenocortical carcinomas were younger, more likely to be female, and more likely to present with metastatic disease. Surgical resection was undertaken in 84% of patients with 69% having R0 resection. While 30-day morbidity was similar between functional and nonfunctional adrenocortical carcinomas, median overall survival was better for nonfunctional adrenocortical carcinomas (median 66 vs 22 months, P = .01). Functional adrenocortical carcinomas was independently associated with shorter survival after adjusting for age, sex, grade, stage, and resection attempt: hazard ratio = 1.5 (95% confidence interval, 1.04–2.14, P = .03). Conclusion: In our cohort, long term survival was worse for all patients with functional tumors. However, when analyzing patients with R0 resection, there was no survival difference between functional and nonfunctional adrenocortical carcinomas, signaling need for better understanding of adrenocortical carcinomas behavior to individualize and optimize treatment strategies.

Original languageEnglish (US)
JournalSurgery (United States)
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Adrenocortical Carcinoma
Survival
Neoplasms
Confidence Intervals
Morbidity

ASJC Scopus subject areas

  • Surgery

Cite this

Sada, A., Asaad, M., Bews, K. A., Thompson, G. B., Young, W. F., Bancos, I., ... McKenzie, T. J. (Accepted/In press). Comparison between functional and non-functional adrenocortical carcinoma. Surgery (United States). https://doi.org/10.1016/j.surg.2019.04.066

Comparison between functional and non-functional adrenocortical carcinoma. / Sada, Alaa; Asaad, Malke; Bews, Katherine A.; Thompson, Geoffrey B.; Young, William Francis; Bancos, Irina; Farley, David R.; Dy, Benzon M.; Lyden, Melanie L.; Habermann, Elizabeth B; McKenzie, Travis J.

In: Surgery (United States), 01.01.2019.

Research output: Contribution to journalArticle

Sada, A, Asaad, M, Bews, KA, Thompson, GB, Young, WF, Bancos, I, Farley, DR, Dy, BM, Lyden, ML, Habermann, EB & McKenzie, TJ 2019, 'Comparison between functional and non-functional adrenocortical carcinoma', Surgery (United States). https://doi.org/10.1016/j.surg.2019.04.066
Sada, Alaa ; Asaad, Malke ; Bews, Katherine A. ; Thompson, Geoffrey B. ; Young, William Francis ; Bancos, Irina ; Farley, David R. ; Dy, Benzon M. ; Lyden, Melanie L. ; Habermann, Elizabeth B ; McKenzie, Travis J. / Comparison between functional and non-functional adrenocortical carcinoma. In: Surgery (United States). 2019.
@article{d4ffe514be8b480e90c200bed5c1fa44,
title = "Comparison between functional and non-functional adrenocortical carcinoma",
abstract = "Background: While roughly half of adrenocortical carcinomas are functional, whether functional status impacts outcomes remains controversial. We compared presentation and survival for functional and nonfunctional neoplasms. Methods: Adult patients presented with adrenocortical carcinomas at the Mayo Clinic were included. Tumor characteristics and outcomes were analyzed. Results: The 266 identified patients presented with stage I (6{\%}), II (33{\%}), III (26{\%}), and IV disease (32{\%}); stage was unknown in 3{\%}. Fifty-three percent of tumors were functional; patients with functional adrenocortical carcinomas were younger, more likely to be female, and more likely to present with metastatic disease. Surgical resection was undertaken in 84{\%} of patients with 69{\%} having R0 resection. While 30-day morbidity was similar between functional and nonfunctional adrenocortical carcinomas, median overall survival was better for nonfunctional adrenocortical carcinomas (median 66 vs 22 months, P = .01). Functional adrenocortical carcinomas was independently associated with shorter survival after adjusting for age, sex, grade, stage, and resection attempt: hazard ratio = 1.5 (95{\%} confidence interval, 1.04–2.14, P = .03). Conclusion: In our cohort, long term survival was worse for all patients with functional tumors. However, when analyzing patients with R0 resection, there was no survival difference between functional and nonfunctional adrenocortical carcinomas, signaling need for better understanding of adrenocortical carcinomas behavior to individualize and optimize treatment strategies.",
author = "Alaa Sada and Malke Asaad and Bews, {Katherine A.} and Thompson, {Geoffrey B.} and Young, {William Francis} and Irina Bancos and Farley, {David R.} and Dy, {Benzon M.} and Lyden, {Melanie L.} and Habermann, {Elizabeth B} and McKenzie, {Travis J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.surg.2019.04.066",
language = "English (US)",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Comparison between functional and non-functional adrenocortical carcinoma

AU - Sada, Alaa

AU - Asaad, Malke

AU - Bews, Katherine A.

AU - Thompson, Geoffrey B.

AU - Young, William Francis

AU - Bancos, Irina

AU - Farley, David R.

AU - Dy, Benzon M.

AU - Lyden, Melanie L.

AU - Habermann, Elizabeth B

AU - McKenzie, Travis J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: While roughly half of adrenocortical carcinomas are functional, whether functional status impacts outcomes remains controversial. We compared presentation and survival for functional and nonfunctional neoplasms. Methods: Adult patients presented with adrenocortical carcinomas at the Mayo Clinic were included. Tumor characteristics and outcomes were analyzed. Results: The 266 identified patients presented with stage I (6%), II (33%), III (26%), and IV disease (32%); stage was unknown in 3%. Fifty-three percent of tumors were functional; patients with functional adrenocortical carcinomas were younger, more likely to be female, and more likely to present with metastatic disease. Surgical resection was undertaken in 84% of patients with 69% having R0 resection. While 30-day morbidity was similar between functional and nonfunctional adrenocortical carcinomas, median overall survival was better for nonfunctional adrenocortical carcinomas (median 66 vs 22 months, P = .01). Functional adrenocortical carcinomas was independently associated with shorter survival after adjusting for age, sex, grade, stage, and resection attempt: hazard ratio = 1.5 (95% confidence interval, 1.04–2.14, P = .03). Conclusion: In our cohort, long term survival was worse for all patients with functional tumors. However, when analyzing patients with R0 resection, there was no survival difference between functional and nonfunctional adrenocortical carcinomas, signaling need for better understanding of adrenocortical carcinomas behavior to individualize and optimize treatment strategies.

AB - Background: While roughly half of adrenocortical carcinomas are functional, whether functional status impacts outcomes remains controversial. We compared presentation and survival for functional and nonfunctional neoplasms. Methods: Adult patients presented with adrenocortical carcinomas at the Mayo Clinic were included. Tumor characteristics and outcomes were analyzed. Results: The 266 identified patients presented with stage I (6%), II (33%), III (26%), and IV disease (32%); stage was unknown in 3%. Fifty-three percent of tumors were functional; patients with functional adrenocortical carcinomas were younger, more likely to be female, and more likely to present with metastatic disease. Surgical resection was undertaken in 84% of patients with 69% having R0 resection. While 30-day morbidity was similar between functional and nonfunctional adrenocortical carcinomas, median overall survival was better for nonfunctional adrenocortical carcinomas (median 66 vs 22 months, P = .01). Functional adrenocortical carcinomas was independently associated with shorter survival after adjusting for age, sex, grade, stage, and resection attempt: hazard ratio = 1.5 (95% confidence interval, 1.04–2.14, P = .03). Conclusion: In our cohort, long term survival was worse for all patients with functional tumors. However, when analyzing patients with R0 resection, there was no survival difference between functional and nonfunctional adrenocortical carcinomas, signaling need for better understanding of adrenocortical carcinomas behavior to individualize and optimize treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=85072271116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072271116&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2019.04.066

DO - 10.1016/j.surg.2019.04.066

M3 - Article

AN - SCOPUS:85072271116

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

ER -